论文部分内容阅读
目的探讨雷贝拉唑对于幽门螺杆菌阳性消化性溃疡的临床治疗效果。方法 90例幽门螺杆菌阳性消化性溃疡患者,随机分为对照组与试验组,每组45例。对照组患者给予奥美拉唑进行治疗,试验组则行雷贝拉唑三联疗法。对比两组服药后的溃疡愈合及其他相关症状的好转情况。结果试验组的溃疡总有效率、治愈率、显效率均高于对照组,治疗后幽门螺杆菌阳性率显著低于对照组,差异均有统计学意义(P<0.05);两组不良反应比较差异无统计学意义(P>0.05),且治疗后血尿常规、肝肾功能检查均未见异常。结论雷贝拉唑对幽门杆菌的根除率高,见效快,可促进溃疡愈合,值得临床推广。
Objective To investigate the clinical effect of rabeprazole on Helicobacter pylori positive peptic ulcer. Methods 90 patients with Helicobacter pylori-positive peptic ulcer were randomly divided into control group and experimental group, with 45 cases in each group. Patients in the control group were treated with omeprazole, and in the test group, rabeprazole triple therapy was used. The improvement of ulcer healing and other related symptoms was compared between the two groups. Results The total effective rate, cure rate and effective rate of ulcer in the experimental group were significantly higher than those in the control group. The positive rate of Helicobacter pylori in the experimental group was significantly lower than that in the control group (P <0.05). The adverse reactions of the two groups were compared The difference was not statistically significant (P> 0.05), and hematuria routine examination, liver and kidney function tests were no abnormalities. Conclusion Rabeprazole has a high eradication rate of H. pylori and is effective in accelerating the healing of ulcer. It is worthy of clinical promotion.